Twinbeech Capital LP Celldex Therapeutics, Inc. Transaction History

Twinbeech Capital LP

$4.99 Billion
Q3 2024

A detailed history of Twinbeech Capital LP transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Twinbeech Capital LP holds 140,502 shares of CLDX stock, worth $3.76 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

140,502

Previous 37,005 279.68%

Holding current value

$3.76 Million

Previous $1.37 Million 248.58%

% of portfolio

0.1%

Previous 0.03%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$32.06 - $44.56 $3.32 Million - $4.61 Million	103,497 Added 279.68%	140,502 $4.77 Million
Q2 2024 Aug 14, 2024	BUY	$32.76 - $42.56 $604,716 - $785,615	18,459 Added 99.53%	37,005 $1.37 Million
Q1 2024 May 15, 2024	SELL	$35.22 - $51.88 $656,183 - $966,576	-18,631 Reduced 50.11%	18,546 $778,000
Q4 2023 Feb 14, 2024	SELL	$22.61 - $40.65 $574,429 - $1.03 Million	-25,406 Reduced 40.6%	37,177 $1.47 Million
Q3 2023 Nov 14, 2023	BUY	$25.45 - $37.46 $1.13 Million - $1.66 Million	44,207 Added 240.57%	62,583 $1.72 Million
Q2 2023 Aug 14, 2023	SELL	$30.29 - $38.28 $778,210 - $983,489	-25,692 Reduced 58.3%	18,376 $623,000
Q1 2023 May 15, 2023	BUY	$34.78 - $47.43 $1.53 Million - $2.09 Million	44,068 New	44,068 $1.59 Million
Q3 2022 Nov 14, 2022	BUY	$22.7 - $37.57 $1.11 Million - $1.84 Million	48,939 New	48,939 $1.38 Million
Q2 2022 Aug 15, 2022	SELL	$20.5 - $37.33 $202,294 - $368,372	-9,868 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$27.64 - $39.32 $75,291 - $107,107	2,724 Added 38.13%	9,868 $336,000
Q4 2021 Feb 14, 2022	BUY	$35.68 - $56.27 $254,897 - $401,992	7,144 New	7,144 $276,000

Others Institutions Holding CLDX

# of Institutions

207

Shares Held

67.3M

Call Options Held

1.69M

Put Options Held

980K

View Full List

About Celldex Therapeutics, Inc.

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.25B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

More about CLDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Twinbeech Capital LP with notifications on news.

Account

Twinbeech Capital LP Celldex Therapeutics, Inc. Transaction History